600252.SS
600252.SS
CNE0000015F9
GUANGXI WUZHOU ZHONGHENG GROUP
Loading chart...

Company Profile

Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for cardiovascular and cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system, and other healthcare applications. It also provides clindamycin hydrochloride injection, esomeprazole sodium injection, esomeprazole magnesium enteric-coated capsules, cefoperazone dry suspension, naloxone hydrochloride injection, and fludarabine phosphate injection. Further, the company is involved in production of oral care, clothing care, and home care products, including toothpaste; health food business; pharmaceutical distribution; project investment and management; real estate development and operation; and cosmetic products businesses. Guangxi Wuzhou Zhongheng Group Co., Ltd was founded in 1993 and is based in Wuzhou, China.

Related stocks

688276.SS
688276.SS • China
CHANGCHUN BCHT BIOTECHNOLOGY CO
17.79 CNY
1.1B USD 1Y -19.6%
000597.SZ
000597.SZ • China
NEP.
4.91 CNY
1.05B USD 1Y -10.2%
002275.SZ
002275.SZ • China
GLSJ
12.35 CNY
1.09B USD 1Y -16%
002349.SZ
002349.SZ • China
JINGHUA PHARM
9.24 CNY
1.15B USD 1Y +28.3%
600129.SS
600129.SS • China
CHONGQING TAIJI IND
13.97 CNY
1.15B USD 1Y -36.3%
002737.SZ
002737.SZ • China
SFPM
11.53 CNY
1.01B USD 1Y -24.8%
002390.SZ
002390.SZ • China
XINBANG PHAR.
3.01 CNY
875.5M USD 1Y -19.5%
002550.SZ
002550.SZ • China
QIANHONG BIO-PHARMA
6.52 CNY
1.25B USD 1Y -28.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
30.9% p.a.
Max Drawdown (5Y)
-57.2%
Sharpe Ratio (5Y)
-0.34
Beta Factor
0.10
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -65.3% in the extended horizon.
ende